Inozyme Pharma's operating expenses for Q2 2024 are not currently available. However, we can infer that the company's operating expenses have not surged in Q2 2024 based on the available data.
- No Record of Surge: There is no record of a surge in Inozyme Pharma's operating expenses in Q2 2024. The company's financial reports for this quarter are not currently available, making it impossible to provide an accurate account of its operating expenses.
- Earnings Estimates: The Q2 2024 earnings estimates for Inozyme Pharma issued by HC Wainwright do not mention any surge in operating expenses. Instead, the analyst E. White forecasts that the company will earn ($0.39) per share for the quarter, down from their prior estimate of ($0.36)1.
- Analyst Ratings: The ratings and estimates from other research analysts, such as Wedbush and Needham & Company LLC, also do not indicate a surge in operating expenses. In fact, Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($0.40) per share for the quarter, up from their prior estimate of ($0.41), suggesting a potential decrease rather than an increase in operating expenses2.
In conclusion, there is no evidence to suggest that Inozyme Pharma's operating expenses surged in Q2 2024. The available data indicates either stability or a slight decrease in operating expenses for the company during this period.